In approximately 50% of human cancers, p53 is detected with mutation or deletion, whereas wild-type p53 cancers loss p53 functions due to overexpression (Eymin et al., 2002) or amplification (Oliner et al., 1992) of MDM2. Here, MDM2 is linked to cancer.